91915:TYSABRI ANTIBODIES
Author PeaceHealth Laboratories
 Print View Attached Docs: |
| Alias Names: |
Natalizumab |
| Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
| Edit Date: |
10/26/2009 |
| Performed: |
Monday |
| Released: |
1-8 days after setup at PeaceHealth Laboratories’ reference lab. |
| CPT Code: |
83516-90 |
| Specimen Collection Details |
| Collection: |
One 7.5 mL serum separator tube (SST). |
| Handling: |
Allow to clot, centrifuge and separate serum from cells and pour into a plastic vial. |
| Stability: |
7 days ambient, 14 days refrigerated, or 30 days frozen. |
| Standard Volume: |
1 mL serum |
| Minimum Volume: |
0.5 mL serum |
| Transport: |
Refrigerated. |
| Comments: |
Tysabri® is a monoclonal antibody therapy used to treat patients with relapsing forms of multiple sclerosis (MS), a serious autoimmune disease that results in damage to the brain and spinal cord. Tysabri® (natalizumab) binds to proteins called alpha-4-integrins, which are found primarily on the surface of white blood cells, and play a role in immune system acitvity. Patients being treated with Tysabri® can develop Tysabri-specific antibodies that may block the therapeutic effect of the treatment. This assay detects antibodies that bind to Tysabri® in vitro; a positive result should not be interpreted as definitive evidence of in vivo blocking activity. |
|
|
Negative |
Antibodies not detected |
|
Positive |
Antibodies detected |
| This assay detects antibodies that bind to Tysabri® in vitro; a positive result should not be interpreted as definitive evidence of in vivo blocking activity.
|
Family Medicine for America's Health